Biochemical-based Anti-Obesity Drug Screening Service
InquiryObesity has evolved from a simple lifestyle concern into a complex, multi-systemic metabolic crisis. The global medical community recognizes it as a primary driver of type 2 diabetes, cardiovascular diseases, and non-alcoholic steatohepatitis (NASH). Developing highly targeted, effective therapeutics is more urgent than ever. While early drug discovery efforts heavily relied on phenotypic, animal-based screening, modern drug discovery demands a more precise approach.
Precision Biochemical-based Anti-Obesity Drug Screening Services
At Protheragen, we bridge this gap by offering a specialized, high-throughput biochemical-based anti-obesity drug screening service. This pre-clinical platform targets the molecular and enzymatic roots of metabolic dysfunction. By focusing on purified enzymes, receptors, and key signaling proteins, we help researchers screen thousands of candidate molecules rapidly and cost-effectively before moving to costly cellular or In Vivo Models.
Core Technologies
To provide unmatched sensitivity and throughput, Protheragen integrates several cutting-edge biochemical and biophysical detection platforms. These technologies are optimized specifically for metabolic and lipid-processing drug targets:
A highly sensitive, mix-and-read technology ideal for high-throughput screening (HTS) of competitive inhibitors targeting key metabolic enzymes.
Optimized for real-time monitoring of lipase activity, cholesterol esterase inhibition, and other lipid-cleaving enzymes.
Provides label-free, real-time kinetic analysis (kon, koff, and KD) to confirm direct physical interactions between small molecules or peptides and their metabolic targets.
Measures changes in the hydration shell or conformation of a protein upon ligand binding, working exceptionally well even in complex buffer systems or with challenging membrane-bound proteins.
Solution Scope
Protheragen offers a highly comprehensive suite of biochemical screening assays. We target the diverse physiological systems that govern energy intake, nutrient absorption, lipid metabolism, and endocrine signaling:
- Lipid Digestion and Gastrointestinal Absorption
Preventing the breakdown and uptake of dietary fats remains a highly effective, clinically validated mechanism for weight management. We screen molecules against key digestive enzymes to identify potent localized inhibitors:
- Pancreatic Lipase Inhibition: High-throughput screening using synthetic fluorogenic substrates to discover novel non-systemic anti-obesity agents.
- Cholesterol Esterase & Phospholipase Assays: Targeting auxiliary lipid-processing enzymes to block systemic lipid uptake.
- Central and Peripheral Appetite Regulation (Receptor-Ligand Biochemistry)
We develop highly sensitive biochemical binding and activation assays targeting the peptide hormones and neurotransmitter receptors that govern satiety and hunger:
- Incretin Receptor Biochemistry (GLP-1R, GIPR, Glucagon Receptor): Cell-free membrane preparation binding assays and GPCR-associated biochemical signaling assays to identify peptide mimetics and small-molecule agonists.
- Melanocortin Receptor 4 (MC4R) & Neuropeptide Y (NPY) Receptors: Screening for selective modulators involved in central energy homeostasis.
- Intracellular Lipid Metabolism and Fatty Acid Synthesis
For programs looking to block fat accumulation at the systemic level, we offer assays targeting the primary enzymatic machinery of de novo lipogenesis and fat storage:
- Fatty Acid Synthase (FASN) & Acetyl-CoA Carboxylase (ACC1/ACC2): Kinetic screening to identify inhibitors that block the synthesis of fatty acids, effectively starving fat storage pathways.
- Diacylglycerol O-Acyltransferase (DGAT1/DGAT2): High-throughput assays targeting the rate-limiting enzymes in triglyceride synthesis to restrict lipid accumulation.
- Energy Expenditure and Mitochondrial Bioenergetics
Our biochemical platform evaluates pathways that stimulate lipid oxidation and enhance energy consumption:
- AMP-Activated Protein Kinase (AMPK) Activation: Screening for direct biochemical activators of AMPK to upregulate catabolic pathways and fatty acid oxidation.
- Carnitine Palmitoyltransferase-1 (CPT-1) Modulation: Identifying compounds that promote mitochondrial fatty acid transport and oxidation.
Inquire with our scientific team to design a custom screening panel for your anti-obesity program.
Workflow
We have mapped out a highly efficient, step-by-step screening pipeline that seamlessly takes your project from initial target preparation all the way to fully validated hit data.
- Target Optimization: Expression and purification of high-activity metabolic enzymes or receptor preparations tailored to your project.
- Assay Development: Custom design and validation of robust biochemical assay conditions to ensure high Z'-factors.
- High-Throughput Screening: Automated, rapid testing of your custom library or our curated anti-obesity compound collections.
- Hit Validation: Secondary screening and dose-response curve generation to confirm true biochemical binding or inhibition.
- Data Delivery: Comprehensive biophysical reporting with detailed kinetic profiles to guide your next structural optimization.
Fields of Application
Because metabolic pathways are deeply interconnected, our biochemical screening platform is built to adapt dynamically across a wide range of drug discovery approaches and therapeutic modalities.
- Small Molecule Drug Discovery
Rapidly identifying and optimizing synthetic small molecules that act as highly selective inhibitors or activators of metabolic enzymes.
- Peptide Therapeutic Design
Assessing the binding affinities and biophysical stabilities of novel peptide agonists targeting GLP-1R/GIPR multi-agonist pathways.
- Natural Product & Nutraceutical Screening
Screening plant extracts, marine-derived compounds, and dietary supplements to discover natural pancreatic lipase inhibitors or metabolic enhancers.
- Target-Based Repurposing
Screening established clinical libraries against newly identified obesity targets to find fast-track clinical candidates.
Advantages
Partnering with Protheragen means more than just outsourcing an assay; you gain a highly sensitive, optimized testing platform and direct access to metabolic experts dedicated to maximizing your screening precision while saving you precious reagents.
Robust Assay Performance and High Z'-Factors
Every single biochemical assay at Protheragen undergoes rigorous validation to guarantee a Z'-factor consistently above 0.7. This high statistical reliability ensures that our screening runs yield minimal false positives or false negatives. Our data show that our standardized high-throughput setups consistently maintain coefficient of variation (CV) values below 5%, giving you absolute confidence in the reproducibility of your data.
Extensive Curated Anti-Obesity Compound Libraries
We offer immediate screening access to our pre-assembled, highly diverse library of bioactive compounds, natural extracts, and metabolic modifiers. This curated collection speeds up target-based discovery campaigns and provides an excellent benchmark for novel drug discovery.
Ultra-low Volume and High-Throughput Efficiency
Our automated liquid-handling systems enable miniaturized assays in 384-well and 1536-well formats, reducing your expensive target protein consumption to microgram levels. This microscale approach allows for highly cost-effective screening campaigns without sacrificing sensitivity.
Deep Scientific Consultation and Project Customization
Unlike standard contract labs, our team consists of senior biochemists with over two decades of metabolic research experience. We work collaboratively to design custom, bespoke assays for novel, challenging, or previously undruggable obesity-related targets.
Partner with Protheragen to Screen Your Targets.
Customer Review
Successful 50,000-Compound Screening Campaign on a Novel Enzyme Target
"We partnered with Protheragen to run a high-throughput biochemical screen against a novel lipid-metabolizing enzyme. Their scientific team developed an incredibly robust assay with a Z'-factor of 0.85. This allowed us to screen our 50,000-compound library smoothly and efficiently. We successfully identified three novel chemical scaffolds that we are now actively optimizing."
Dr. S. J., Director of Discovery Chemistry
High-Precision Biophysical Validation for Complex Peptide Therapeutics
"The biophysical validation services at Protheragen, particularly their SPR and MST assays, provided the exact kinetic data we needed to confirm the binding of our multi-receptor peptide agonists. Their data package was highly professional, clear, and perfectly formatted for our regulatory submissions. We look forward to collaborating with them on our upcoming metabolic programs."
Dr. M. V., Staff Scientist
Frequently Asked Questions
-
Why choose a biochemical screen over a cell-based assay for anti-obesity drug discovery?
Biochemical assays isolate the direct interaction between your compound and the target enzyme or receptor. This removes confounding cellular factors like cell membrane permeability, cytotoxicity, and off-target metabolism. This allows for a precise determination of binding kinetics and inhibition constants, IC50 or Ki.
-
What is the typical turnaround time for a standard 10,000-compound biochemical screen?
Once the assay is fully validated and we reach the screening-ready stage, we can complete a 10,000-compound screen in about 2 to 3 weeks, which includes full hit validation and data curation.
-
Can Protheragen work with membrane-bound metabolic receptors?
Yes, we have specialized protocols for isolating stable membrane fractions or using detergent-solubilized preparations. These are ideal for GPCRs like GLP-1R or MC4R, allowing for highly accurate binding assays.
-
Do you offer custom assay development for novel metabolic targets?
Absolutely. If your target enzyme or receptor is not currently in our catalog, our scientific team will work closely with you to express, purify, and develop a validated biochemical assay tailored to your needs.
-
How do you handle poorly soluble compounds or natural extracts?
Our platforms are optimized to tolerate low levels of DMSO (typically up to 1-2% v/v) without loss of enzymatic activity. For complex natural products, we use specialized buffer conditions to prevent compound aggregation and minimize assay interference.
-
What biophysical techniques do you use to confirm primary screening hits?
We primarily utilize surface plasmon resonance (SPR) and microscale thermophoresis (MST) to obtain label-free, real-time kinetic measurements of direct molecular binding.
-
Can you accommodate peptide-based drugs in your screening platform?
Yes, our binding and activation assays are perfectly suited for evaluating GLP-1, GIP, and glucagon receptor co-agonists or multi-agonist peptide compounds.
-
What quality control parameters do you use to ensure screening reliability?
We monitor the Z'-factor, signal-to-background ratio, and CV across all assay plates. We also include reference inhibitors on every plate to ensure assay performance remains highly consistent.
-
Can we provide our own compound library for the screen?
Yes, we accept custom libraries in dry format or pre-dissolved in DMSO. Our liquid handling systems can process a wide variety of plate formats.
-
What are the next steps if we find promising hits in your biochemical screen?
Once you identify validated biochemical hits, you can transition them directly into our cellular screening assays, ADME profiling, or structural biology services to guide further optimization.
Contact Us
At Protheragen, we help drug developers accelerate metabolic and anti-obesity discovery programs through robust, reliable, and high-throughput biochemical screening. Our advanced biophysical platforms, paired with decades of drug discovery expertise, ensure your pipeline is built on a solid foundation of precise molecular data. Contact Protheragen for more information or a custom quote.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.